Four years non-diabetic status after impaired glucose tolerance diagnosis cuts cardiovascular risks

De­spite be­ing an ear­ly crit­ic of the In­fla­tion Re­duc­tion Act, Pfiz­er told in­vestors on Mon­day that the leg­is­la­tion is like­ly to have a “mod­est” im­pact

Despite the paradigm-changing impact of immunotherapy on cancer treatment, only a minority of patients obtain long-term benefits from the treatment. The most common estimate is